A Cross-Functional Perspective on Scientific Collaboration, Regulatory Compliance, and Quality System Integration
American Journal of Technology · 13.06.2026 · 5 (8) · 1-14
DOI: 10.58425/ajt.v5i8.561 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Technology, online erschienen am 13.06.2026. Verfasst von Snehal Godse. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
This paper examines the specific and structured role of pharmaceutical Research and Development (R&D) in supporting manufacturing departments during the investigation, root cause determination, Corrective and Preventive Action (CAPA) design, and regulatory documentation of process deviations, Out-of-Specification (OOS) results, and Out-of-Trend (OOT) observations. The study further identifies the scientific competencies, data assets, and communication mechanisms through which R&D contributes to manufacturing quality resolution and proposes a formal cross-functional support model consistent with ICH Q10 and current Good Manufacturing Practice (cGMP) expectations.
Methods
A review of regulatory guidance documents, ICH quality guidelines, and published pharmaceutical quality literature was conducted. The study also referenced laboratory investigation trending data reported by Reji et al. (2023) from a pharmaceutical R&D company. Regulatory frameworks, including FDA 21 CFR Parts 210/211, ICH Q8, Q9, and Q10, and WHO TRS 961, were analyzed in relation to R&D’s cross-functional support obligations.
Results
The review found that R&D contributes to manufacturing quality event resolution through the provision of process development history, Critical Process Parameter (CPP) and Critical Quality Attribute (CQA) linkage data, and formulation science expertise for root cause investigations. R&D also provides Phase 2A manufacturing review support during OOS investigations, stability and degradation knowledge for OOT impact assessments, and scientifically grounded CAPA design. The study identified organizational siloing, inadequate knowledge-transfer documentation, and the absence of formal R&D–manufacturing interface protocols as the primary barriers to effective cross-functional support.
Conclusion
R&D plays a critical role in supporting manufacturing departments in the investigation and resolution of deviations, OOS results, and OOT events. Effective utilization of R&D expertise enhances root cause analysis, CAPA development, and regulatory compliance, thereby contributing to improved quality management and the prevention of recurring quality failures in pharmaceutical production. Recommendation: The study recommends the adoption of a formalized R&D support model built on shared knowledge platforms, defined escalation pathways, joint investigation protocols, and co-owned CAPA processes. Such a model is essential for sustainable manufacturing compliance and effective management of pharmaceutical quality events.
Zitieren
APA
Godse, S. (2026). A Cross-Functional Perspective on Scientific Collaboration, Regulatory Compliance, and Quality System Integration. American Journal of Technology, 5(8), 1-14. https://doi.org/10.58425/ajt.v5i8.561
Vancouver
Godse S. A Cross-Functional Perspective on Scientific Collaboration, Regulatory Compliance, and Quality System Integration. American Journal of Technology. 2026;5(8):1-14. doi:10.58425/ajt.v5i8.561
BibTeX
@article{Godse2026,
author = {Godse, Snehal},
title = {A Cross-Functional Perspective on Scientific Collaboration, Regulatory Compliance, and Quality System Integration},
journal = {American Journal of Technology},
year = {2026},
volume = {5},
number = {8},
pages = {1--14},
doi = {10.58425/ajt.v5i8.561}
}
EUVIMED